196 related articles for article (PubMed ID: 17698848)
1. Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.
Jacobs MT; Zhang YW; Campbell SD; Rudnick G
J Biol Chem; 2007 Oct; 282(40):29441-7. PubMed ID: 17698848
[TBL] [Abstract][Full Text] [Related]
2. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.
Bulling S; Schicker K; Zhang YW; Steinkellner T; Stockner T; Gruber CW; Boehm S; Freissmuth M; Rudnick G; Sitte HH; Sandtner W
J Biol Chem; 2012 May; 287(22):18524-34. PubMed ID: 22451652
[TBL] [Abstract][Full Text] [Related]
3. Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Coleman JA; Yang D; Zhao Z; Wen PC; Yoshioka C; Tajkhorshid E; Gouaux E
Nature; 2019 May; 569(7754):141-145. PubMed ID: 31019304
[TBL] [Abstract][Full Text] [Related]
4. Control of serotonin transporter phosphorylation by conformational state.
Zhang YW; Turk BE; Rudnick G
Proc Natl Acad Sci U S A; 2016 May; 113(20):E2776-83. PubMed ID: 27140629
[TBL] [Abstract][Full Text] [Related]
5. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
Wei D; Maisonneuve IM; Kuehne ME; Glick SD
Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
[TBL] [Abstract][Full Text] [Related]
6. The cytoplasmic substrate permeation pathway of serotonin transporter.
Zhang YW; Rudnick G
J Biol Chem; 2006 Nov; 281(47):36213-20. PubMed ID: 17008313
[TBL] [Abstract][Full Text] [Related]
7. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.
Mash DC; Staley JK; Baumann MH; Rothman RB; Hearn WL
Life Sci; 1995; 57(3):PL45-50. PubMed ID: 7596224
[TBL] [Abstract][Full Text] [Related]
8. Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
Efange SM; Mash DC; Khare AB; Ouyang Q
J Med Chem; 1998 Nov; 41(23):4486-91. PubMed ID: 9804688
[TBL] [Abstract][Full Text] [Related]
9. Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine.
Alburges ME; Hanson GR
Brain Res; 1999 Nov; 847(1):139-42. PubMed ID: 10564747
[TBL] [Abstract][Full Text] [Related]
10. Conformational dynamics of the human serotonin transporter during substrate and drug binding.
Möller IR; Slivacka M; Nielsen AK; Rasmussen SGF; Gether U; Loland CJ; Rand KD
Nat Commun; 2019 Apr; 10(1):1687. PubMed ID: 30976000
[TBL] [Abstract][Full Text] [Related]
11. Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analogue as a molecular reporter.
Rasmussen SG; Carroll FI; Maresch MJ; Jensen AD; Tate CG; Gether U
J Biol Chem; 2001 Feb; 276(7):4717-23. PubMed ID: 11062247
[TBL] [Abstract][Full Text] [Related]
12. Effect of ibogaine on cocaine-induced efflux of [3H] dopamine and [3H] serotonin from mouse striatum.
Sershen H; Hashim A; Lajtha A
Pharmacol Biochem Behav; 1996 Apr; 53(4):863-9. PubMed ID: 8801590
[TBL] [Abstract][Full Text] [Related]
13. Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding.
Wall SC; Innis RB; Rudnick G
Mol Pharmacol; 1993 Feb; 43(2):264-70. PubMed ID: 8429827
[TBL] [Abstract][Full Text] [Related]
14. Application of electrophysiological method to study interactions between ibogaine and cocaine.
Binienda Z; Beaudoin MA; Thorn BT; Sadovova N; Skinner RD; Slikker W; Ali SF
Ann N Y Acad Sci; 2000 Sep; 914():387-93. PubMed ID: 11085337
[TBL] [Abstract][Full Text] [Related]
15. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding.
Chen JG; Sachpatzidis A; Rudnick G
J Biol Chem; 1997 Nov; 272(45):28321-7. PubMed ID: 9353288
[TBL] [Abstract][Full Text] [Related]
16. Ligand effects on cross-linking support a conformational mechanism for serotonin transport.
Tao Z; Zhang YW; Agyiri A; Rudnick G
J Biol Chem; 2009 Dec; 284(49):33807-14. PubMed ID: 19837674
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats.
Szumlinski KK; Maisonneuve IM; Glick SD
Psychopharmacology (Berl); 1999 Jul; 145(2):227-33. PubMed ID: 10463325
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes.
Tavoulari S; Forrest LR; Rudnick G
J Neurosci; 2009 Jul; 29(30):9635-43. PubMed ID: 19641126
[TBL] [Abstract][Full Text] [Related]
19. The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes.
Wells GB; Lopez MC; Tanaka JC
Brain Res Bull; 1999 Apr; 48(6):641-7. PubMed ID: 10386845
[TBL] [Abstract][Full Text] [Related]
20. Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies.
Broderick PA; Phelan FT; Eng F; Wechsler RT
Pharmacol Biochem Behav; 1994 Nov; 49(3):711-28. PubMed ID: 7862728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
